膝关节镜辅助微创手术治疗复杂性胫骨平台骨折的疗效分析

目的:探讨膝关节镜辅助微创手术治疗复杂性胫骨平台骨折的疗效。方法:搜集2013年2月-2015年1月期间我院收治的确诊为复杂性胫骨平台骨折患者104例,按照随机数字表法分为微创组和对照组,每组各52例。对照组采用传统切开复位钢板内固定术治疗,微创组采用膝关节镜辅助微创手术治疗;观察两组患者临床各项指标、膝关节功能HSS评分以及术后并发症发生率。结果:术后微创组下床活动时间、完全负重下地时间和骨折愈合时间显著低于对照组(P0.05);三个月后的关节活动度、一年后的膝关节功能优良率显著高于对照组(P0.05);术后微创组并发症发生率为9.62%(5/52),显著低于对照组的23.08%(12/52),差异具有统计学意义(P0.05)。结论:膝关节镜辅助微创手术治疗复杂性胫骨平台骨折,临床疗效显著,术后膝关节功能恢复好,并发症发生率低,值得临床推广应用。     

血清miR-203a、miR-31-5p、miR-19b-1-5p水平与股骨颈骨折患者骨折延迟愈合的关系及其预测价值分析

摘要 目的：探讨血清微小核糖核酸（miR）-203a、miR-31-5p、miR-19b-1-5p水平与股骨颈骨折患者术后骨折延迟愈合的关系及对术后骨折延迟愈合的预测价值。方法：选择2020年1月~2022年10月在徐州医科大学附属医院行内固定治疗的292例新鲜股骨颈骨折患者为研究对象。于术后4周复查时,检测患者血清miR-203a、miR-31-5p、miR-19b-1-5p水平;并根据其骨折愈合情况分为延迟组（n=36）和愈合组（n=256）。采用多因素Logistic回归分析股骨颈骨折患者术后骨折延迟愈合的影响因素。采用受试者工作特征（ROC）曲线分析血清miR-203a、miR-31-5p、miR-19b-1-5p对股骨颈骨折患者术后骨折延迟愈合的预测价值。结果：术后4个月复查时,骨折延迟愈合发生率为12.33%。两组年龄、吸烟史、合并糖尿病组间比较,差异有统计学意义（P＜0.05）。愈合组血清miR-203a、miR-31-5p、miR-19b-1-5p水平均高于延迟组（P<0.05）。多因素Logistic回归分析结果显示,年龄≥60岁、合并糖尿病、血清miR-203a、miR-31-5p、miR-19b-1-5p水平降低是股骨颈骨折患者术后骨折延迟愈合的独立危险因素（P＜0.05）。ROC曲线结果显示,三者联合检测的曲线下面积（AUC）（0.95CI）为0.841（0.738~0.936）,高于各指标单独应用时的AUC,三者联合检测的灵敏度和特异度亦高于单一指标检测。结论：血清miR-203a、miR-31-5p、miR-19b-1-5p在股骨颈骨折术后骨折延迟愈合患者中呈低表达,是骨折延迟愈合的独立危险因素,三者联合检测对股骨颈骨折患者骨折延迟愈合具有较高的预测价值。     

经伤椎椎弓根螺钉固定治疗脊柱骨折的疗效及对患者疼痛、Cobb角的影响

目的:探讨经伤椎椎弓根螺钉固定治疗脊柱骨折的疗效及对患者疼痛、Cobb角的影响。方法:选择2013年2月至2018年2月我院接诊的脊柱骨折患者80例作为研究对象,以随机数表法分为观察组(n=41)和对照组(n=39)。对照组采用跨伤椎固定治疗,观察组采用经伤椎椎弓根螺钉固定治疗。比较两组患者临床手术指标、日本骨科协会评估治疗(JOA)评分、视觉模拟评分(VAS)、椎体压缩率、Cobb角水平及伤椎椎体高度。结果:观察组患者手术时间、术中出血量及住院时间均显著低于对照组(P0.05);治疗后,两组患者JOA评分、VAS评分均明显改善(P0.05),且观察组患者VAS评分显著低于对照组(P0.05);治疗后,两组患者椎体压缩率、Cobb角水平均明显改善(P0.05),且观察组患者椎体压缩率、Cobb角水平显著低于对照组(P0.05);两组患者治疗前椎体前、后缘高度无明显差异;治疗后,两组患者椎体前、后缘高度均明显改善(P0.05),且观察组患者椎体前、后缘高度显著高于对照组(P0.05)。结论:脊柱骨折患者采用经伤椎椎弓根螺钉固定治疗栓效果显著,可改善患者疼痛、Cobb角水平,值得临床推广。     

穴位贴敷联合阶段性康复功能训练对股骨颈骨折术后患者功能康复、血清疼痛因子和骨代谢标志物的影响

摘要 目的：探讨穴位贴敷联合阶段性康复功能训练对股骨颈骨折术后患者功能康复、血清疼痛因子和骨代谢标志物的影响。方法：纳入四川省骨科医院2021年1月~2021年10月期间收治的股骨颈骨折患者150例。根据信封抽签法将患者分为对照组（75例）和观察组（75例）,对照组接受阶段性康复功能训练,观察组接受穴位贴敷联合阶段性康复功能训练,两组均干预3个月。3个月后,观察两组功能康复、视觉疼痛模拟评分法（VAS）评分、血清疼痛因子和骨代谢标志物情况,记录两组术后并发症发生率。结果：两组干预3个月后Barthel指数和Harris髋关节评分均较干预前升高,且观察组高于对照组（P<0.05）。两组干预1个月后、干预2个月后、干预3个月后视觉疼痛模拟评分法（VAS）评分逐渐下降,且观察组低于对照组（P<0.05）。两组干预3个月后骨特异性碱性磷酸酶（BALP）、骨保护素（OPG）升高,且观察组高于对照组;抗酒石酸盐酸性磷酸酶异构体（TRACP-5b）、Ⅰ型胶原羧基端肽β特殊序列（βCTX）水平降低,且观察组低于对照组（P<0.05）。两组干预3个月后缓激肽（BK）、前列腺素E2（PGE2）、5-羟色胺（5-HT）、脑内神经肽Y（NPY）水平降低,且观察组低于对照组（P<0.05）。两组术后并发症发生率组间对比无统计学差异（P>0.05）。结论：穴位贴敷联合阶段性康复功能训练可促进对股骨颈骨折患者术后功能恢复,减轻术后疼痛,可能与调节骨代谢相关标志物水平有关。     

LCP结合自体髂骨联合RBX植骨治疗非感染萎缩型肱骨干骨不连的体会

目的:探讨锁定加压钢板(Locked compression plate,LCP)结合自体髂骨联合重组合异种骨(recombinant bone xenograft,RBX)植骨治疗非感染萎缩型肱骨干骨不连的疗效及相关体会。方法:于2009年2月-2015年9月期间,应用LCP结合自体髂骨联合RBX植骨治疗了15例非感染萎缩型肱骨干骨不连。结果:本组获随访9-29个月,骨不连均获得愈合。肩关节功能优良率86.7%,肘关节功能优良率100%。结论:依据本组研究及相关文献报道,LCP结合自体髂骨植骨联合RBX植骨可提高骨不连愈合率。     

Bone Quality as Measured by Trabecular Bone Score in Normocalcemic Primary Hyperparathyroidism

ObjectiveThe impact of normocalcemic hyperparathyroidism (NHPT) on bone quality remains largely unexplored. We aimed to investigate the usefulness of trabecular bone score (TBS) assessment in NHPT and the accuracy of TBS in predicting vertebral fractures (VFs) in NHPT.MethodsIn this multicentric cross-sectional study, we assessed the TBS in 47 subjects with NHPT, 41 with primary hyperparathyroidism (PHPT), and 39 age- and sex-matched control subjects.ResultsTBS values did not differ among the 3 groups. The prevalence of low TBS (TBS < 1.2) was 23.4% in NHPT, 26.8% in PHPT, and 15.4% in controls, without statistically significant differences between groups. However, we found a lower lumbar spine Z-score adjusted for TBS (LS Z-score1TBS) in PHPT participants when compared with controls (-0.48 ± 1.06 vs 0.07 ± 0.93, P = .017). In NHPT group, LS Z-score1TBS did not detect patients with overall VFs (threshold, -0.15; area under the curve, 0.45; 95% CI, 0.253-0.648; accuracy, 55.3%). Instead, it was useful for moderate-severe VFs (threshold, 0.55; area under the curve, 0.81; 95% CI, 0.62-0.996; accuracy, 83%). In PHPT subjects also, TBS did not predict VFs.ConclusionIn NHPT, TBS is not reduced. When adjusted for TBS, the LS Z-score might predict moderate-to-severe VFs.     

Osteoporosis Treatment After Osteoporotic Fractures: Data From a Single Medical Center

ObjectiveMost patients do not receive osteoporosis treatment after osteoporotic fracture. This study reviewed osteoporosis treatment after osteoporotic fractures in a center without a Fracture Liaison Service.MethodsWe identified all patients with hip, vertebral, humeral or radial fractures, evaluated in Meir Medical Center, in 2017. The exclusion criteria were not a Clalit Health Services member, high-energy fracture or 30-day postoperative mortality. The primary endpoint was osteoporosis drugs issued within 12 months of fracture. Secondary endpoints included bone densitometry and 1-year mortality.ResultsFive-hundred-eighty-two patients (average age 78.6 ± 11.1 years, 75.8% women) were included. There were 321 (55.5%) hip, 84 (14.1%) humeral, 33 (5.6%) vertebral, and 144 (24.7%) radial fractures. Osteoporosis drugs were issued to 26.5% of the patients; those with humeral fractures received the least (21.4%) and vertebral, the most (30.3%; P = .51). Bone densitometry was performed in 23.2% of patients. One-year mortality after hip fracture was 12.1%, followed by humeral (3.6%; P < .05). Logistic regression showed that previous treatment (odds ratio [OR] = 7.4; 95% confidence interval [CI] 3.6–15.2), bone densitometry (OR = 4.4; 95% CI 2.6–7.4) and endocrinology visit (OR = 2.6; 95% CI, 1.4–4.6) were the most important factors associated with treatment.ConclusionFewer than one third of patients received pharmacotherapy within 1 year after fracture. Because pharmacotherapy reduces future fractures and mortality, we recommend that medical staff who care for patients with fracture adopt practical and effective strategies to increase treatment rates among patients with osteoporotic fractures.